Paediatric drug optimization for leprosy: meeting report, 28–29 April and 14 May 2026
Overview
This report presents the outcomes of the paediatric drug optimization (PADO) exercise for leprosy, convened by WHO in April and May 2026 to identify short- and long-term therapeutic priorities for children. The exercise reviewed medicines currently available for leprosy prevention, treatment and management of reactions, alongside emerging products in the research and development pipeline, to guide stakeholders towards priority formulations and strategies for improving access to age-appropriate therapeutics.
The exercise established the first PADO lists for leprosy. The access list prioritizes dispersible clofazimine tablets and age-appropriate prednisolone formulations, while the priority list identifies scored dispersible tablets of rifampicin and dapsone for development. The watch list includes bedaquiline, telacebec, dovramilast and rifapentine as candidates for further investigation. Additional research priorities address paediatric dosing, pharmacokinetics, formulation suitability and regulatory evidence requirements. The report highlights opportunities to leverage formulations developed for tuberculosis programmes and support coordinated efforts among researchers, manufacturers, regulators, funders and implementing partners to improve access to appropriate medicines for children with leprosy.